Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Caffeine · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| Single Arm | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| Midazolam | DRUG | Each subject will receive midazolam on Days 1 and 12. |
| Caffeine | DRUG | Each subject will receive caffeine on Days 1 and 12. |
| Rosuvastatin | DRUG | Each subject will receive rosuvastatin on Days 2 and 13. |
| EDP-305 | DRUG | Each subject will receive EDP-305 on Days 5 through 15. |
Inclusion Criteria: * An informed consent document signed and dated by the subject. * Healthy male and female subjects of any ethnic origin between the ages of 18 and 55 years, inclusive. * Female subjects must be of non-childbearing potential. Exclusion Criteria: * Clinically relevant evidence o...
Caffeine is an investigational small molecule being studied in NASH, or nonalcoholic steatohepatitis. It is currently in Phase 1 clinical development. The drug is being evaluated for its potential role in treating this metabolic liver condition, though it remains investigational and has not been approved for any use.
Caffeine is being developed by Enanta Pharmaceuticals, Inc., a biopharmaceutical company traded on NASDAQ under the ticker ENTA. The company is conducting clinical research on this investigational drug for NASH, a form of nonalcoholic fatty liver disease.
Caffeine is in Phase 1 clinical development. It is an investigational drug being studied for NASH, and it has not been approved by regulatory authorities. The drug is still in early-stage clinical testing to evaluate its safety and pharmacological properties.
Caffeine has been studied in one completed Phase 1 clinical trial, identified as NCT03187496. This was a drug-drug interaction study involving EDP-305, midazolam, caffeine, and rosuvastatin in healthy volunteers. The trial enrolled 24 participants and was conducted in the United States.
No, Caffeine is not the same as EDP-305. In the clinical trial NCT03187496, caffeine was used as a probe substrate to study drug-drug interactions with EDP-305, which is the investigational drug being developed by Enanta Pharmaceuticals. Caffeine itself is being studied as part of this interaction assessment.